 NEW YORK--BUSINESS WIRE--- RCKT GeneTherapy--Rocket Pharmaceuticals, Inc. NASDAQ: RCKT Rocket, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that it has commenced an underwritten public offering of 175 million of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of its common stock sold in the public offering. All the share 